Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LATE-R TRIAL
2024-512835-53-00Phase 2Authorised
- Sponsor
- GELTAMO
- Start
- Sep 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axicabtagene ciloleucel in diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma, follicular lymphoma (FL) and 1 more, sponsored by GELTAMO. Primary endpoint: Complete metabolic response at Month 3 (investigator assessment). Planned start Sep 2024; status: authorised.
02
Drugs
axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphomafollicular lymphoma (FL)aggressive B-cell lymphoma
Beyond the preview
Go deeper on 2024-512835-53-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512835-53-00.